Asset Details
Do you wish to reserve the book?
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
Do you wish to request the book?
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
2013
Overview
In this small, preliminary study of sofosbuvir, a nucleotide inhibitor of HCV polymerase, treatment with sofosbuvir and ribavirin, without peginterferon, was effective in achieving a sustained virologic response in patients with HCV genotype 1, 2, or 3 infection.
Recent progress in the treatment of chronic hepatitis C virus (HCV) infection — the approval of the first-generation protease inhibitors telaprevir and boceprevir — has benefited many but not all patients with HCV infection. One quarter of patients with HCV genotype 1 infection who have not received previous therapy and 71% of those with no response to previous therapy do not have a sustained virologic response with protease-inhibitor–based regimens.
1
No direct-acting antiviral agents have yet been approved for patients with HCV genotype 2 or 3 infection.
The standard of care for all patients with HCV infection continues to include 24 . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Antibiotics. Antiinfectious agents. Antiparasitic agents
/ Antiviral Agents - adverse effects
/ Antiviral Agents - therapeutic use
/ Biological and medical sciences
/ Female
/ Genotype
/ Hepacivirus - isolation & purification
/ Hepatitis C, Chronic - blood
/ Hepatitis C, Chronic - drug therapy
/ Humans
/ Interferon-alpha - adverse effects
/ Interferon-alpha - therapeutic use
/ Male
/ Pharmacology. Drug treatments
/ Polyethylene Glycols - adverse effects
/ Polyethylene Glycols - therapeutic use
/ Recombinant Proteins - adverse effects
/ Recombinant Proteins - therapeutic use
/ Uridine Monophosphate - adverse effects
/ Uridine Monophosphate - analogs & derivatives
